Cargando…
Antibody therapy for COVID-19
PURPOSE OF REVIEW: To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period. RECENT FINDINGS: Limited clinical effect of classical passive immunotherapy (plasma therapy, hyper...
Autores principales: | Hammarström, Lennart, Marcotte, Harold, Piralla, Antonio, Baldanti, Fausto, Pan-Hammarström, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577309/ https://www.ncbi.nlm.nih.gov/pubmed/34570010 http://dx.doi.org/10.1097/ACI.0000000000000787 |
Ejemplares similares
-
Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding
por: Morgan, Clare, et al.
Publicado: (2022) -
Global immunoglobulin supply: steaming towards the iceberg?
por: Prevot, Johan, et al.
Publicado: (2020) -
Updates of cancer hallmarks in patients with inborn errors of immunity
por: Wang, Yating, et al.
Publicado: (2022) -
Dendritic cell analysis in primary immunodeficiency
por: Bigley, Venetia, et al.
Publicado: (2016) -
Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective
por: Hammarström, Lennart, et al.
Publicado: (2020)